Linked Life Data

19020392

Source:http://linkedlifedata.com/resource/pubmed/id/19020392

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9 Suppl
pubmed:dateCreated
2008-11-21
pubmed:abstractText
Most cases of adult GH deficiency (AGHD) result from hypothalamic-pituitary tumors or their treatment. Some experimental and clinical observations suggest that GH may possess a mitogenic potential, thus raising the question of whether it is a safe treatment in patients with a previous pituitary tumor. Few study results have been reported on this topic. All of them have inevitable methodological flaws that limit their conclusions. However, all studies report that replacement therapy with GH does not seem to increase the risk of tumor progression or recurrence, when compared to historical or matched controls. Considering the slow-growing nature of most of these benign tumors and the absence of conclusive evidence from the available studies, a continuous imaging surveillance and longer follow-up periods are nevertheless mandatory for a definite statement on the safety of GH treatment in patients with previous pituitary tumors.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0391-4097
pubmed:author
pubmed:issnType
Print
pubmed:volume
31
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
75-8
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Replacement therapy with growth hormone and pituitary tumor recurrence: the relevance of the problem.
pubmed:affiliation
Pituitary Unit, Department of Neurosurgery, San Raffaele Scientific Institute, Vita-Salute University, 20132-Milan, Italy. losa.marco@hsr.it
pubmed:publicationType
Journal Article, Review, Evaluation Studies